Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Lord Abbett & CO. LLC

Posted by Geri Gentry on Jun 13th, 2026

Lord Abbett & CO. LLC trimmed its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 0.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,449,607 shares of the company’s stock after selling 26,356 shares during the period. Lord Abbett & CO. LLC’s holdings in Teva Pharmaceutical Industries were worth $107,662,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Clal Insurance Enterprises Holdings Ltd boosted its stake in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Teva Pharmaceutical Industries by 3.8% in the 4th quarter. Quadrant Capital Group LLC now owns 22,726 shares of the company’s stock worth $709,000 after buying an additional 836 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Teva Pharmaceutical Industries by 80.9% in the 4th quarter. Advisors Asset Management Inc. now owns 6,871 shares of the company’s stock worth $214,000 after buying an additional 3,073 shares during the last quarter. Laurel Oak Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $1,135,000. Finally, Advocate Investing Services LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $53,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on TEVA shares. Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Check Out Our Latest Research Report on TEVA

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $34.58 on Friday. The firm has a market capitalization of $39.75 billion, a P/E ratio of 26.00, a P/E/G ratio of 3.53 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The business’s 50-day simple moving average is $33.28 and its 200-day simple moving average is $31.96.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Insider Activity

In related news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. This trade represents a 34.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 421,470 shares of company stock worth $14,570,945 in the last ninety days. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.